使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning and welcome to the Amneal Pharmatical's third quarter 2025 earnings call. I will now turn the call over to Amneal's Head of Investor Relations Tony Dimeo. Please go ahead.
早安,歡迎參加Amneal製藥公司2025年第三季財報電話會議。現在我將把電話轉交給Amneal的投資人關係主管Tony Dimeo。請繼續。
Anthony Dimeo - Head of Investor Relations
Anthony Dimeo - Head of Investor Relations
Good morning and thank you for joining Amneal Pharmaceuticals third quarter 2025 earnings call. Today, we issued a press release reporting Q3 results. The earnings press release and presentation are available at amneal.com.
早安,感謝各位參加Amneal Pharmaceuticals 2025年第三季財報電話會議。今天,我們發布了第三季業績新聞稿。財報新聞稿和簡報可在amneal.com上取得。
Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions are forward-looking statements that are based solely on information that is now available to us.
本次電話會議中就非歷史事實事項所作的某些陳述,包括但不限於管理階層的展望或預測,均為前瞻性陳述,僅基於我們目前掌握的資訊。
Please see the section entitled cautionary statements on forward-looking statements for factors that may impact future performance. We also discussed non-GAAP measures. Information on use of these measures and reconciliation to GAAP are in the earnings release and presentation.
請參閱題為「前瞻性陳述的警示性聲明」的部分,以了解可能影響未來績效的因素。我們也討論了非GAAP財務指標。有關這些措施的使用情況以及與 GAAP 的核對信息,請參閱盈利報告和演示文稿。
On the call today are Chirag Patel and Chintu Patel, co-Founders and co-CEOs, Tasios Konidaris, CFO, our commercial leaders, Andy Boyer for Affordable Medicines, and Joe Renda for Specialty.
今天參加電話會議的有共同創辦人兼聯合執行長 Chirag Patel 和 Chintu Patel,財務長 Tasios Konidaris,我們的商業領導人,平價藥品負責人 Andy Boyer,以及專科藥品負責人 Joe Renda。
I will now hand the call over to Chirag.
現在我將把電話交給奇拉格。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Thank you, Tony. Good morning, everyone. We're pleased with our strong third quarter performance. Which represents another consecutive quarter of growth with revenues of $785 million and adjusted EBITDA of $160 million. And I'm new, we focus on delivering innovative and affordable medicines that make a difference for patients and providers.
謝謝你,托尼。各位早安。我們對第三季強勁的業績感到滿意。這標誌著該公司連續第二季實現成長,營收達 7.85 億美元,調整後 EBITDA 達 1.6 億美元。我是新來的,我們專注於提供創新且價格合理的藥物,為患者和醫療服務提供者帶來改變。
Since our founding in 2002, we have strategically expanded from generics into specialty, injectables, biosimilars, GLP-1, and complex medicines. This portfolio diversification has driven significant and sustainable top and bottom line growth.
自 2002 年成立以來,我們已從仿製藥策略性地擴展到專科藥物、注射劑、生物相似藥、GLP-1 和複雜藥物。這種投資組合多元化推動了營收和利潤的顯著且可持續成長。
From 2019 through now, annual revenues have grown 11% and adjusted EBITDA has grown 13% on a CAGR basis. With growth in each of the last six consecutive years, we're very confident our momentum will continue in the years ahead.
從 2019 年至今,年收入複合年增長率為 11%,調整後 EBITDA 複合年增長率為 13%。過去六年我們每年都實現了成長,因此我們非常有信心,未來幾年我們的成長動能將繼續保持下去。
Today, there are multiple growth drivers that are shaping the future of Amneal. First, in specialty segments. CREXONT for Parkinson's disease continue to outperform expectations.
如今,多種成長驅動因素正在塑造 Amneal 的未來。首先,在專業領域。用於治療帕金森氏症的 CREXONT 的療效持續超出預期。
One year post launch, CREXONT is delivering strong results across all key indicators, notably, about 80% of prescriptions are coming from IR patients, underscoring the success of our strategy to expand into the broader patient population. We're confident in peak US sales of $300 million to $500 million for CREXONT.
上市一年後,CREXONT 在所有關鍵指標上都取得了強勁的成績,尤其值得一提的是,約 80% 的處方來自 IR 患者,這凸顯了我們向更廣泛的患者群體擴展戰略的成功。我們有信心CREXONT在美國的銷售額高峰將達到3億至5億美元。
Next, our Brekiya, autoinjector for migraine and cluster headache has now launched. This is the first and only product allowing patients to self-administer the same medication used in hospitals. It addresses an unmet need for patients who have historically had to go to the hospital for relief.
接下來,我們用於治療偏頭痛和叢集性頭痛的自動注射器 Brekiya 也已上市。這是首款也是唯一一款允許患者自行服用與醫院所用藥物相同的藥物的產品。它滿足了以往需要去醫院尋求治療的患者的未滿足需求。
Second, in GLP-1s, our strategic collaboration with Metsera positions us very well to play a meaningful role in this very large therapeutic category over the time. Metsera's broad portfolio of injectable and oral weight loss programs continue to quickly advance through the clinical phase.
其次,在 GLP-1 領域,我們與 Metsera 的策略合作使我們能夠在這個龐大的治療領域中發揮重要作用,並隨著時間的推移不斷擴大影響力。Metsera 的注射和口服減重產品組合豐富多樣,並且正在快速推進臨床試驗階段。
Third, in biosimilars, we are on track to have six marketed biosimilar products by 2027. Led by a symbolist to bXOLAIR for the US market over $4 billion for this key allergy and asthma product to our largest current biosimilar opportunity. Last month we submitted over BLA for bXOLAIR biosimilar and we are well positioned to be among the first two entrants in this growing market.
第三,在生物相似藥方面,我們預計在 2027 年前推出六款上市的生物相似藥產品。在像徵性投資者的帶領下,bXOLAIR 在美國市場獲得了超過 40 億美元的收入,而這款關鍵的過敏和氣喘產品是我們目前最大的生物相似藥機會。上個月,我們提交了 bXOLAIR 生物相似藥的 BLA 申請,我們很有希望成為這個不斷增長的市場中的前兩家進入者之一。
Both in complex genetics and injectables in our affordable medicine segment, we continue to receive approval for meaningful new products, including respiridone injectable, sodium oxalate, and beatoprost ophthalmic QR, among others.
無論是在複雜的遺傳學領域還是在我們價格合理的藥品領域的注射劑領域,我們都不斷獲得有意義的新產品的批准,其中包括利培酮注射劑、草酸鈉和貝托前列素眼用緩釋劑等。
We expect the segment will continue to grow, driven by our diversified portfolio of complex products and steady cadence of impactful new launches.
我們預計,在多元化的複雜產品組合和持續推出有影響力的新產品的推動下,該細分市場將繼續成長。
Finally, our healthcare segment continues to provide diversification, stability and growth with a broad portfolio for government distribution and unit those channels.
最後,我們的醫療保健業務板塊繼續提供多元化、穩定性和成長,擁有廣泛的政府分銷管道產品組合,並支援這些管道。
In summary. Our growing portfolio is creating meaningful value for patients by expanding access and advancing standards of care and for providers by delivering a broader and more differentiated portfolio and for investors by driving consistent growth and margin expansion.
總之。我們不斷成長的產品組合透過擴大病患就醫途徑和提高照護標準,為病患創造有意義的價值;透過提供更廣泛、更具差異化的產品組合,為醫療服務提供者創造有意義的價值;透過推動持續成長和利潤率提升,為投資者創造有意義的價值。
Over time we have strategically evolved from generics to innovative and complex medicines, and our current chapter of growth the most exciting one yet.
隨著時間的推移,我們已從仿製藥策略性地發展到創新複雜藥物,而我們目前的成長階段是迄今為止最令人興奮的。
As we grow and expand our portfolio, we're advancing towards a strategic goal of becoming America's number one affordable medicines company.
隨著我們不斷發展壯大,我們的產品組合也不斷擴展,我們正朝著成為美國第一大平價藥品公司的策略目標邁進。
I'll turn the call over to Chintu.
我把電話轉給欽圖。
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Thank you, Chirag, and good morning. As always, I will begin by thanking the global Amneal family. Your unwavering dedication and commitment continue to drive our success. The recipe for continued strong performance is clear operational excellence, robust innovation, and strategic portfolio expansion.
謝謝你,奇拉格,早安。首先,我要像往常一樣感謝全球的Amneal大家庭。你們堅定不移的奉獻和投入是我們成功的關鍵。持續強勁業績的秘訣在於:卓越的營運、強勁的創新和策略性的產品組合擴張。
First, in operations. Our global manufacturing network and leading capabilities remain a core strategic advantage. We continuously strengthen our operational efficiency through digitalization, automation, and cost discipline, while at the same time innovating in new complex dosage forms to expand our reach. Furthermore, with one of the largest US pharmaceutical manufacturing footprints made in America remains the key differentiator for Amneal in the industry.
首先,在營運方面。我們的全球製造網絡和領先能力仍然是我們的核心策略優勢。我們不斷透過數位化、自動化和成本控制來提高營運效率,同時不斷創新,研發新的複雜劑型,以擴大我們的業務範圍。此外,在美國本土生產的藥品數量在美國規模最大,這仍然是Amneal在該行業中的關鍵差異化優勢。
In GLP-1s, our collaboration with Metsera is progressing very well. Leveraging our expertise in R&D and manufacturing. We are building two state of the art facilities, one for large scale peptide production and another for advanced sterile field finish designed to produce prefilled syringes, cartridges, or wires.
在 GLP-1 領域,我們與 Metsera 的合作進展非常順利。充分利用我們在研發和製造方面的專業知識。我們正在建造兩座最先進的設施,一座用於大規模勝肽生產,另一座用於先進的無菌現場精加工,旨在生產預灌封注射器、藥筒或導線。
At the same time at Metsera's injectable and oral clinical programs continue to show strong efficacy and product profiles, with timelines bringing us closer to entering this fast growing market. In affordable medicines portfolio, we look to launch 20 to 30 new products each year. So far in 2025, we have launched 170 new products with approvals for 13 more to launch in the future.
同時,Metsera 的注射劑和口服劑臨床計畫繼續展現出強大的療效和產品特性,其時間表使我們離進入這個快速成長的市場更近了一步。在平價藥品組合方面,我們計劃每年推出 20 至 30 種新產品。截至 2025 年,我們已經推出了 170 款新產品,另有 13 款產品已獲准在未來推出。
Importantly, it is not just the number of new launches, but the value of these recent launches and approvals and how they position Amneal for future growth.
重要的是,重要的不僅是新產品的推出數量,還有這些近期推出的產品和獲得的批准的價值,以及它們如何為 Amneal 的未來成長奠定基礎。
For years, our focus has been on complex generics innovation. Including injectables, ophthalmics, inhalation, and other advanced dosage forms, essentially the most complex drug device combinations in pharmaceuticals.
多年來,我們一直專注於複雜仿製藥的創新。包括注射劑、眼用製劑、吸入劑和其他先進劑型,本質上是製藥領域最複雜的藥物器材組合。
And as a result of years of hard work and strategic focus, we are in the midst of a concentrated wave of affordable medicines, new product launches coming to market in the near term.
經過多年的努力和策略重點,我們正處於平價藥品集中上市的浪潮中,近期將有新產品上市。
To highlight all of these, we have a new slide in the earnings presentation with a list of some of the key launches ongoing now and coming up next.
為了突出所有這些,我們在收益簡報中新增了一張投影片,列出了一些正在進行且即將推出的關鍵產品。
In the third quarter, we expanded our portfolio with several important approvals across key therapeutic areas, including our first long acting injectable respiridone extended release in the mental health space, sodium oxybate for narcolepsy, and bimatoprost for glaucoma, as well as new otic and injectable products like multi-dose epinephrine for hospitals. Just yesterday we are pleased to receive tentative approval for our first meter dose inhalation product belomethasone dipropionate, generic for QR.
第三季度,我們在多個關鍵治療領域獲得了多項重要批准,從而擴展了我們的產品組合,包括我們在精神健康領域首個長效注射用利培酮緩釋劑、用於治療嗜睡症的羥丁酸鈉、用於治療青光眼的比馬前列素,以及用於醫院的多劑量腎上腺素等新的耳用和注射產品。就在昨天,我們很高興地收到我們首個計量吸入產品丙酸貝洛米松(QR 的通用名)的初步批准。
This is the first of several new inhalation products expected in the coming years, as inhalation is a new growth factor starting in 2026. For years we have been discussing the strategic portfolio shift towards the complex products and with so many meaningful launches, we are at an inflection point.
這是未來幾年預計將推出的幾款新型吸入產品中的第一款,因為吸入療法從 2026 年開始將成為一個新的成長因素。多年來,我們一直在討論向複雜產品進行策略性組合轉變,隨著眾多意義重大的產品發布,我們正處於一個轉折點。
Looking ahead, we have 69 AND spending, of which 64% are complex products and 44 additional products in development, of which 95% are complex products. We continue to focus our R&D on high growth, high impact products across dosage forms such as inhalation, Microspheres, Liposomes, and 505(b)(2) specialty injectables.
展望未來,我們有 69 個 AND 支出項目,其中 64% 為複雜產品;另有 44 個產品正在開發中,其中 95% 為複雜產品。我們將繼續把研發重點放在高成長、高影響力的產品上,涵蓋吸入劑、微球、脂質體和 505(b)(2) 特殊注射等劑型。
With this strategic portfolio expansion and robust pipeline, we are reshaping our affordable medicine business and expect our strong momentum to drive meaningful growth and value creation for the years to come.
憑藉這一戰略性的產品組合擴張和強大的產品線,我們正在重塑我們的平價藥品業務,並期望我們強勁的發展勢頭將在未來幾年推動有意義的成長和價值創造。
In biosimilars, we remain focused on building our leadership position over time. The most exciting near term opportunity is our biosimilar to bXOLAIR, where we submitted our BLA in September ahead of schedule. Alongside bXOLAIR, we are advancing other key programs including Dinazumab, with multiple new biosimilar launches expected in 2026 and 2027.
在生物相似藥領域,我們將繼續專注於逐步鞏固我們的領先地位。近期最令人興奮的機會是我們與 bXOLAIR 類似的生物製劑,我們已於 9 月提前提交了生物製品許可申請 (BLA)。除了 bXOLAIR 之外,我們還在推進其他關鍵項目,包括 Dinazumab,預計將在 2026 年和 2027 年推出多個新的生物相似藥。
In specialty, our CREXONT on open label Phase 4 study is progressing very well. We are very pleased with early results and look forward to sharing additional data later this year on real world, good on time performance that further supports CREXONT clinical value and differentiation for Parkinson's patients.
就專科藥物而言,我們的 CREXONT 開放標籤 4 期研究進展非常順利。我們對初步結果非常滿意,並期待在今年稍後分享更多真實世界中的良好按時表現數據,這將進一步支持 CREXONT 對帕金森氏症患者的臨床價值和差異化作用。
We continue to work on several specialty R&D initiatives in focus area of CNS and endocrinology, and we look forward to sharing more as these programs advances.
我們繼續致力於中樞神經系統和內分泌學領域的幾項專業研發計劃,並期待隨著這些計劃的進展與大家分享更多資訊。
In summary, we are driving operational excellence, advancing our innovation agenda, and expanding our portfolio to deliver robust growth and leadership across our business areas.
總而言之,我們正在努力提升營運效率,推進創新議程,並擴大產品組合,以在各個業務領域實現強勁成長和領先地位。
I will hand it over to Tasios.
我會把它交給塔西奧斯。
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Thank you, Chintu and good morning everyone. Q3 was another terrific quarter with continued and sustainable strong growth across our three business segments. The resilient and consistent growth is a testament to our strategic choices, diversified portfolio, and robust execution.
謝謝你,Chintu,大家早安。第三季度又是一個非常棒的季度,我們三大業務部門都維持了持續強勁的成長。持續穩定的成長證明了我們的策略選擇、多元化的投資組合和強有力的執行力。
In addition, we further strengthened our balance sheet with strong cash flow generation, reduced net leverage ratio, and increased our expected full year bottom line guidance. So all in all, an excellent quarter.
此外,我們透過強勁的現金流產生能力進一步加強了資產負債表,降低了淨槓桿率,並提高了全年獲利預期。總而言之,這是一個非常出色的季度。
As I usually do all start with our Q3 and year-to-date results, move on to our balance sheet and our updated 2025 guidance. Starting with the third quarter, total company revenues grew 12% to $785 million.
像往常一樣,我先介紹我們的第三季和年初至今的業績,然後介紹我們的資產負債表和更新後的 2025 年業績指引。從第三季開始,公司總營收成長了 12%,達到 7.85 億美元。
Our affordable medicines revenue grew 8% year over year to $461 million, reflecting strong performance across our broad portfolio of more than 280 products.
我們平價藥品營收年增 8% 至 4.61 億美元,反映出我們 280 多種產品的廣泛組合均表現強勁。
Key contributors to our growth this quarter were products launched in 2024 and 2025, which added $24 million in revenue and included a number of 505(b)(2) that meet real customer needs. Specialty revenue was again very strong in Q3, up 8% year over year to $125 million driven by CREXONT and UNITHROID.
本季我們成長的主要貢獻者是 2024 年和 2025 年推出的產品,這些產品增加了 2,400 萬美元的收入,其中包括一些滿足客戶實際需求的 505(b)(2) 產品。第三季度,特藥營收再次表現強勁,年增 8% 至 1.25 億美元,主要得益於 CREXONT 和 UNITHROID 的強勁表現。
In the third quarter, as expected, aftercare revenues grew 24% to $199 million fueled by strong growth in the government. AvKARE's growth continues to be driven by strong underlying demographics, as well as providing substantial savings to the government with timely access to innovative and very often newly available affordable medicine products.
第三季度,如預期,售後服務收入成長了 24%,達到 1.99 億美元,主要得益於政府業務的強勁成長。AvKARE 的成長持續受到強勁的潛在人口結構驅動,同時,透過及時提供創新且通常是新推出的平價藥品,為政府節省了大量資金。
Moving down the P&L, Q3 adjusted gross margins were 42.7%, down 150 basis points year over year. However, margins on a year to day basis are up 130 basis points.
從損益表來看,第三季調整後的毛利率為 42.7%,較去年同期下降 150 個基點。然而,與去年同期相比,利潤率上升了130個基點。
We view our year-to-date gross margins growth as indicative of our underlying performance, and we're confident of growing our full year gross margin compared to 2024.
我們認為今年迄今的毛利率成長反映了我們的基本業績,我們有信心全年毛利率將比 2024 年有所增長。
The expansion of gross margin is primarily driven by the innovation and strength of new product launches, as well as our relentless focus on driving, operating expense efficiencies.
毛利率的成長主要得益於新產品的創新和強勁表現,以及我們持續致力於提高營運成本效率。
Third quarter adjusted EBITDA over $160 million, grew 1% driven by top-line growth, higher gross profit and higher commercial costs in a port of CREXONT and Brekiya. It is worth noting that our third quarter adjusted EBITDA includes $22.5 million of R&D milestone payments related to the solar PLA filing.
第三季調整後 EBITDA 超過 1.6 億美元,成長 1%,主要得益於 CREXONT 和 Brekiya 港口的營收成長、毛利增加以及商業成本上升。值得注意的是,我們第三季調整後的 EBITDA 包括與太陽能 PLA 申請相關的 2,250 萬美元研發里程碑付款。
Lastly, Q3 earnings per share of $0.17 through 6% versus prior year on the back of lower interest expenses. Let me now shift to our year-to-date performance where total revenue increased 7%, driven by growth of 5% in affordable medicines, 11% growth in specialty, and 8% growth in AvKARE.
最後,由於利息支出減少,第三季每股收益為 0.17 美元,比去年同期成長 6%。現在讓我來談談我們今年迄今為止的業績,總收入增長了 7%,其中平價藥品增長了 5%,專科藥品增長了 11%,AvKARE 增長了 8%。
Adjusted [EBITDA] grew 9% and adjusted EPS grew 35% year to year, year-to-date. The drivers of a year to day growth are very similar to those of the third quarter.
經調整的 [EBITDA] 年成長 9%,經調整的每股盈餘較去年同期成長 35%。推動年增速的因素與第三季增速的因素非常相似。
Turning to the balance sheet, as a reminder, we're very pleased to complete our full debt refinancing in July, which reduces interest costs substantially and extends debt maturities from 2028 to 2032. Also, net leverage at the end of Q3 was 3.7 times, down from 3.9 times at the end of last year.
再來看資產負債表,提醒一下,我們非常高興地宣布,我們在 7 月完成了全部債務再融資,這大幅降低了利息成本,並將債務到期日從 2028 年延長至 2032 年。此外,第三季末的淨槓桿率為 3.7 倍,低於去年年底的 3.9 倍。
Overall, our capital allocation priorities remain consistent. That is invest in higher return organic revenue growth.
整體而言,我們的資本配置優先事項保持不變。也就是說,要投資報酬率更高的有機收入成長。
Number two, reducing net leverage below 3 times over the course of time. And finally, remain strategic with business development opportunities that enhance our growth profile and value creation.
第二,隨著時間的推移,將淨槓桿率降低到 3 倍以下。最後,要保持策略性,把握能夠提升公司成長前景和價值創造的業務發展機會。
Moving on to our financial guidance, and we're pleased that for the second consecutive quarter to update our guidance for revenues, we continue to expect the range of $3 billion to $3.1 billion.
接下來談談我們的財務預期,我們很高興連續第二季更新營收預期,我們仍然預期營收將在 30 億至 31 億美元之間。
We have raised the low end of our adjusted EBITDA by $10 million to a new range between $675 million and $685 million. And we have raised the full range of adjusted GPS by $0.05 to a new range between $0.75 and $0.80.
我們將調整後 EBITDA 的下限提高了 1,000 萬美元,新的範圍為 6.75 億美元至 6.85 億美元。我們將調整後的 GPS 價格範圍提高了 0.05 美元,新的範圍為 0.75 美元至 0.80 美元。
Lastly, we expect continued strong operating cash flow between $300 million to $330 million this year and further year over year debt and net leverage reduction.
最後,我們預計今年將繼續保持強勁的營運現金流,在 3 億美元至 3.3 億美元之間,債務和淨槓桿率將逐年下降。
Looking to 2026 and beyond, we continue to expect top and bottom line growth supported by our diversified portfolio and multiple growth drivers, including CREXONT, Brekiya, new biosimilars such as bXOLAIR, and a very strong wave of new affordable medicines and continued growth in AvKARE.
展望 2026 年及以後,我們預計在多元化的產品組合和多種成長驅動因素的支持下,營收和利潤將繼續成長,這些驅動因素包括 CREXONT、Brekiya、bXOLAIR 等新型生物相似藥,以及大量價格實惠的新藥和 AvKARE 的持續成長。
Furthermore, our focus on profitable growth, operating expense synergies, and lower interest costs, a strong catalyst for strong shareholder value creation.
此外,我們專注於獲利成長、營運費用綜效和降低利息成本,這為創造強勁的股東價值提供了強有力的催化劑。
With that, I'll turn the call back to Chirag.
這樣,我就把電話轉回給奇拉格了。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Thank you to our strong Q3 results and updated 2025 guidance underscore the continued momentum across our diversified business. We remain confident. As we advance this chapter. Toward becoming America's number one affordable medicines company.
由於我們強勁的第三季業績和更新後的 2025 年業績指引,我們多元化業務的持續發展勢頭得以彰顯。我們依然充滿信心。隨著我們推進本章的進展。目標是成為美國排名第一的平價藥品公司。
Let's now open the call for Q&A.
現在進入問答環節。
Operator
Operator
(Operator Instructions) l̥
(操作說明)lÌ¥
Matt Dellatorre, Goldman Sachs.
Matt Dellatorre,高盛集團。
Matthew Dellatorre - Analyst
Matthew Dellatorre - Analyst
Hey, great, thanks, and congrats on the quarter. Maybe on the Metsera partnership, could you give us, your latest thinking on how the acquisition by Pfizer may impact the agreement? I know you've said prior you don't expect this to change anything given there's a change in control clause and that you all collaborated with Pfizer in the past.
嘿,太好了,謝謝,也恭喜你本季業績出色。關於與Metsera的合作,您能否談談您對輝瑞收購可能對該協議產生何種影響的最新看法?我知道你之前說過,鑑於存在控制權變更條款,而且你們過去都與輝瑞公司有過合作,你不認為這會改變任何事情。
So just curious on your latest thinking there, and then we obviously saw this morning there's another bid for Metsera by Novo at a higher price.
所以,我很好奇你最近的想法,而且我們今天早上也看到Novo對Metsera提出了更高的收購要約。
So maybe your thoughts on that dynamic as well and if there's any kind of meaningful difference from an Amneal perspective in terms of who ultimately acquires the company.
所以,您對此有何看法?從 Amneal 的角度來看,最終收購公司的一方是否有任何實質的差異?
And then secondly, FDA came out with new draft guidance yesterday that essentially removes the need for comparative Phase 3 efficacy studies for biosimilars. Just curious on your thoughts, in terms of how this impacts Amneal on the broader industry and market dynamics going forward. Thanks a lot.
其次,FDA昨天發布了新的指導草案,該草案基本上取消了對生物相似藥進行比較性3期療效研究的必要性。我很好奇您對此有何看法,認為這將對Amneal以及更廣泛的行業和市場動態產生怎樣的影響。多謝。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Good morning, Matt. I guess we chose the right partner, Metsera is, doing well, I guess, and obviously there are two bidders now, and, for us like it's really good. We've been working with Metsera for the last couple of years and, have devoted lots of resources from, science, engineering, operations, manufacturing, very close partner, great relationship, great company, and that programs are advanced as well.
早安,馬特。我想我們選對了合作夥伴,Metsera 目前發展得不錯,而且現在顯然有兩個競標者,這對我們來說真的很好。過去幾年我們一直與 Metsera 合作,投入了大量資源,涵蓋科學、工程、營運、製造等領域。我們是非常緊密的合作夥伴,關係很好,公司也很棒,而且他們的專案也很先進。
As you know Matt, I cannot comment on the current events, between Pfizer and Novo, and either one of them, and the, stands to win because of the higher name recognition on both brands, with our partnership with, and it has rights to 18 countries to market the products, and agreement for, supply, which is very meaningful as well.
如你所知,馬特,我無法對輝瑞和諾和諾德之間的當前事件發表評論,也無法確定哪一方會勝出,因為我們與輝瑞和諾和諾德的合作關係使其品牌知名度更高,並且擁有在 18 個國家/地區銷售產品的權利以及供應協議,這也非常有意義。
So stay tuned and, as it progresses, we'll keep you updated. The second question, it's awesome we've been experiencing that, we know whether from our partners what FDA is willing to do now since they have lots of data over the last almost more than 12, 13 years they've seen the biosimilars, the safety data, the biosimilars data from the clinics as well.
請關注,我們隨時向您報告最新進展。第二個問題,我們一直在經歷這一點,這真是太棒了。我們從合作夥伴那裡了解到,FDA現在願意做什麼,因為他們在過去12、13年累積了大量數據,他們看到了生物相似藥、安全數據以及來自臨床的生物相似藥數據。
So finally, they are in agreement to push for a more biosimilar approval, cut down the cost and time by half. And this is where Metsera vertical integration would play a key role because it still will take three to five years for competitors to catch up.
最終,他們同意推動生物相似藥的審批,將成本和時間減少一半。而這正是 Metsera 垂直整合將發揮關鍵作用的地方,因為競爭對手還需要三到五年的時間才能趕上。
So it's great for the industry. Most importantly, it's great for the patients. It's going to create great access and FTA and HHS is behind us and entire CMS to call out all the games that are being played by the brand companies and really promote and create a market for biosimilars.
所以這對業界來說是件好事。最重要的是,這對患者來說非常好。這將創造良好的市場准入機會,聯邦運輸管理局 (FTA) 和美國衛生與公眾服務部 (HHS) 以及整個醫療保險和醫療補助服務中心 (CMS) 都將支持我們,揭露品牌公司玩弄的各種花招,真正促進和創造生物相似藥的市場。
And then making those biosimilars in the United States will even further give the advantages for the companies that invest in America. So we're very excited. There are 170 molecules, only 30 are being worked on the 90 not being worked on and biologic says you know represents half of the value for the entire pharmaceutical spend, and most of those drugs are very expensive, bringing affordable access. This is our mission allows them to take the leadership position and what we've been saying is become America's number one affordable medicines company allows us to in the future if we get the vertical integration done as soon as possible to have bigger, broader portfolio of 20 to 30 biosimilars and keep adding five to seven every year.
而在美國生產這些生物相似藥,將進一步為投資美國的公司帶來優勢。所以我們非常興奮。目前已知有 170 種分子,但只有 30 種正在研發,其餘 90 種沒有研發。生物製劑佔整個製藥支出的一半,而且大多數藥物價格昂貴,因此,生物製劑的研發需要提供價格合理的途徑。我們的使命是讓他們佔據領導地位,而我們一直說的是,成為美國第一大平價藥品公司,這將使我們在未來能夠盡快完成垂直整合,從而擁有更大、更廣泛的產品組合,包括 20 到 30 種生物類似藥,並且每年新增 5 到 7 種。
I hope that answers your question on where the biosimilars are headed. Very exciting.
希望這能解答你關於生物相似藥未來發展方向的問題。太令人興奮了。
Matthew Dellatorre - Analyst
Matthew Dellatorre - Analyst
That's great, thank you.
太好了,謝謝。
Operator
Operator
Leszek Sulewski, Truist Securities.
Leszek Sulewski,Truist Securities。
Leszek Sulewski - Analyst
Leszek Sulewski - Analyst
Great, yeah, thank you for taking my questions. Just to follow-up, for each question actually on the biosimilars front, how does that change your kind of overall strategy, given this kind of draft guidance potentially finalized as it stands.
太好了,謝謝你回答我的問題。為了進一步說明,針對生物相似藥方面的每個問題,鑑於目前這種草案指導意見可能會最終定稿,這會如何改變你們的整體策略?
And then on the opposing side to that, do you see potentially for the increased competition where the price erosion curves ultimately resemble the traditional generics.
另一方面,您是否認為隨著競爭加劇,價格侵蝕曲線最終可能會與傳統仿製藥相似?
And Metsera, I understand there are clauses in place with the current contract that you have, you're building out the facilities in India. How is your kind of thinking about that sway the new change of control of the company and then potentially, your commercialization rights in the emerging markets. Are there any kind of safeguards in place for you to retain those, and I do have a follow-up.
梅特塞拉,據我了解,你們目前的合約中有相關條款,你們正在印度建設設施。您認為這種影響會如何體現在公司控制權的變更,以及由此可能產生的新興市場的商業化權利?你們是否有任何保障措施來保留這些資訊?我還有一個後續問題。
Thank you.
謝謝。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Thank you, Les. So let's expand more on overall strategy for biosimilars. So it would expedite the development timing. It would, cut down the cost by almost half. And both are very encouraging, but you still need big biologics manufacturing site.
謝謝你,萊斯。那麼,讓我們進一步探討生物相似藥的整體策略。這樣可以加快開發進度。這樣一來,成本就能降低近一半。兩者都非常令人鼓舞,但你仍然需要大型生物製劑生產基地。
You need the liters of capacity. You need the teams of hundreds of analytical people manufacturing engineering to get all these done and with the US standards. So with FDA and then obviously EMA follows European standards are similar.
你需要以公升為單位的容量。你需要數百名分析人員和製造工程師組成的團隊才能按照美國標準完成所有這些工作。所以,FDA和EMA都遵循歐洲標準,兩者之間是類似的。
So the companies, for example, Indian companies who are focused on emerging markets in biology for years, for 20 years, they would have to build a brand new infrastructure that that is for the United States and all the products from the beginning for the United States, so. If a new increases its footprint through the vertical integration, it will give us the advantage over next five years.
例如,那些多年來(20 年)專注於新興生物學市場的印度公司,將不得不從一開始就為美國建立一個全新的基礎設施,並生產所有面向美國的產品。如果一家新公司透過垂直整合擴大其市場份額,那麼在未來五年內,這將為我們帶來優勢。
Then your question on the pricing and competition yes, competitors will enter, but it's still expensive. We're not talking about $2 million development of complex genetics or $5 million right? We're talking still about $40 million, $50 million, $60 million based on a molecule and still it takes a lot of CapEx to have the infrastructure to produce those and science capabilities and engineering, so it's complicated manufacturing.
至於你問的價格和競爭問題,是的,會有競爭對手進入市場,但價格還是很貴。我們說的不是耗資 200 萬美元或 500 萬美元的複雜基因工程研發,對吧?我們說的仍然是基於一種分子的 4000 萬美元、5000 萬美元、6000 萬美元,而且仍然需要大量的資本支出來建立生產這些分子的基礎設施、科學能力和工程技術,所以製造過程很複雜。
The pricing of biosimilars are way higher than the small molecule. So even when you hear the tagline of 80% reduction. If your investment is $40 million to $60 million, you're still doing great. As long as you can execute, be there and select the molecules which are two competitors, three competitors enter first so you have advantage of insurance coverage, working with private labels.
生物相似藥的價格遠高於小分子藥物。所以即使你聽到「減少 80%」這樣的宣傳語。如果你的投資金額在 4000 萬美元到 6000 萬美元之間,那麼你的投資仍然非常成功。只要你能執行,到場並選擇分子,兩到三個競爭對手率先進入,這樣你就能在保險覆蓋方面獲得優勢,並與自有品牌合作。
You're doing buy and build model all these three you do have marketing set up as well, which Amneal does have.
你們這三家公司都採用了收購和自建模式,而且你們也都建立了行銷體系,Amneal 就是這樣一家公司。
So that is how I see the biosimilar industry blossoming over the next one, two, three, four, five, I see up to 10 years. Even with the competition, it's a great marketplace. The dollars are large, complications are very much there, and there are many molecules to go after.
所以,我認為生物相似藥產業在未來一到十年內將會蓬勃發展。即使競爭激烈,它仍然是一個很棒的市場。資金數量龐大,複雜因素也很多,需要研究的分子種類也很多。
Now you can select $500 million molecule. You can select $1billion molecule. Then no need to just keep going after the $10 million and $20 billion that would face 10 competitors. So it is a competitive industry. It was supposed to be competitive and it will create huge value for the patient and providers.
現在你可以選擇價值 5 億美元的分子。你可以選擇價值10億美元的分子。那就沒有必要繼續追逐那 1,000 萬美元和 200 億美元,就去面對 10 個競爭對手了。所以這是一個競爭激烈的行業。它本應具有競爭力,並將為患者和醫療服務提供者創造巨大價值。
So and then complete backing of the US government, which is fantastic, to push this rightfully so, and that was the main intent when the law was passed. So we remain very big player and will be to win bars for the United States market particularly, and it also allows us to go global as well.
因此,美國政府給予了全力支持,這非常棒,推動這項法案的實施是理所當然的,這也是該法案通過時的主要目的。因此,我們仍然是市場上的重要參與者,尤其能夠贏得美國市場的酒吧,這也有助於我們走向全球。
Metsera, your second question mark, it's the same answer that we cannot discuss much at this point, as we have a solid partnership with Metsera, and we look forward to work with whoever the new partner is. And we're very excited actually, so stay tuned and, we'll update you at the right time.
Metsera,你提出的第二個問題,答案和之前一樣,我們現在無法過多討論,因為我們與 Metsera 有著穩固的合作關係,我們期待與新的合作夥伴攜手共進。我們其實非常興奮,敬請期待,我們會適時通知大家。
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director
And on a biosimilars I like to add. Let's just on a biosimilar I'd like to add the point was Chira was saying first of all this draft guidance is very encouraging for the entire industry, but unlike small molecules, still in the large molecules, there are multiple barriers of entry.
關於生物相似藥,我想補充一點。就生物相似藥而言,我想補充一點,Chira 首先表示,這份指導草案對整個行業來說非常令人鼓舞,但與小分子藥物不同,大分子藥物仍然存在多重准入壁壘。
So the speed to market still it's a lot longer, plus the capacity, unlike small molecule where there was a floodgate of people filing 20, 30, 40 NDAs, it's not possible, there are 100, 1200, 1500 biologic products, where, only 20 or 30 are being worked on.
因此,上市速度仍然要慢得多,而且產能也有限。不像小分子藥物那樣,很多人會提交 20、30、40 份新藥申請,現在不可能發生這種情況。生物製劑有 100、1200、1500 種,但只有 20 或 30 種正在研發中。
So still there are manufacturing, science, analytical is a very strong aspect of development, and the R&D does not allow you to take 5, 10 biosimilars a year. So still the next 10 years, if you have a head start and have a vertical integration. There are so many opportunities you can do and with this new draft guidance, still, three to four filing is kind of max for most of the companies.
所以,製造、科學、分析仍然是研發中非常重要的一個面向,但研發並不允許你一年推出 5、10 種生物相似藥。所以,未來 10 年,如果你有先發優勢並實現了垂直整合,仍然很有希望。您可以做很多事情,而且根據這份新的指導草案,對於大多數公司來說,提交三到四份文件已經是極限了。
Leszek Sulewski - Analyst
Leszek Sulewski - Analyst
That was very insightful and extensive color on that. I appreciate it. Thank you.
那真是非常有見地且內容豐富的描述。謝謝。謝謝。
Maybe just one more if I could squeeze it in for tassels. SG&A Q3 run rate, a little bit of a pickup is this kind of a good proxy as we move forward and then second, maybe high level. As you think about capital location, you're kind of getting into that 3x leverage range over the next couple of years, what do you think of in terms of kind of BD? Is it more transformative, or kind of continuation of tokens or even on the biosimilars front, but just in general, capital locations priorities over the next couple of years. Thank you.
如果能擠出點空間做流蘇的話,也許可以再加一個。SG&A 第三季運行率略有回升,這可以作為我們展望未來的一個很好的參考指標,其次,也許可以從更高層次來衡量。考慮到未來幾年資本配置可能會達到 3 倍槓桿率,您認為在業務拓展方面應該如何應對?它更具變革性,還是代幣的某種延續,甚至是在生物相似藥方面,但總的來說,未來幾年的資本配置優先事項是什麼?謝謝。
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Yeah, more or less, let me answer your first questions about the run rate of the sales and marketing expense. I think Q3 is pretty indicative. I think you can, where we are because it includes kind of full commercialization expense for CREXONT, right, which was an additive this year compared to last year. It includes a little bit of a kind of getting the market set up for, the exciting new launch of Brekiya.
好的,差不多是這樣。讓我先回答你關於銷售和行銷費用運行率的第一個問題。我認為第三季的情況很有代表性。我認為可以,因為我們在這裡包含了 CREXONT 的全部商業化費用,對吧,這是今年比去年增加的費用。其中包括為 Brekiya 的令人興奮的新產品發布進行市場準備工作。
So I think that's a good run rate. That's, around the -- it's our priorities here have not changed, and that is how do we balance kind of building capabilities and products and diversification. In a thoughtful, doing the right deals, and at the same time structuring the deals in a way that is affordable, right?
所以我覺得這個運行率還不錯。也就是說,我們的優先事項沒有改變,那就是如何平衡能力建構、產品開發和多元化發展。經過深思熟慮,達成正確的交易,同時以可負擔的方式構建交易,對嗎?
So that was the case, for example, you're going to go back to AvKARE many years ago, right? We acquired 65% of that of that business, did not acquired the whole thing. It was the right smart thing from a balanced perspective.
比如說,你要回到很多年前的 AvKARE,對吧?我們收購了該公司 65% 的股份,但並沒有收購全部股份。從平衡的角度來看,這是明智之舉。
It also kept the management team engaged with the substantial skin in the game, right? And that allowed us to deliver that business quickly. Then you saw the material deal last year. Again, thoughtful deal, where the partner contributed substantial amount of cash. There's substantial grants that we are expecting to receive from the India government.
這也讓管理團隊保持了高度的參與度,對吧?這使我們能夠迅速完成這項業務。然後你看到了去年的那筆實質交易。再次強調,這是一筆經過深思熟慮的交易,合作夥伴投入了大量現金。我們預計將從印度政府獲得大量撥款。
And the CapEx is over the course of time. And that's the way we're thinking about this. The rental comes up. We've been very vocal for probably the last couple of years about our desire to vertically integrate in the biosimilar space, so we continue to look at that and we'll update, folks, whether there's something to update in about, but you can continue to expect, discipline and doing the right deal at the right time.
而且資本支出是分階段進行的。我們就是這麼考慮這個問題的。租房子的事兒又提了出來。在過去的兩年裡,我們一直非常公開地表達了我們希望在生物相似藥領域進行垂直整合的願望,所以我們會繼續關注這一點,如果有任何進展,我們會及時更新。但你們可以繼續期待,我們會秉持嚴謹的態度,在適當的時機達成適當的交易。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Thank you.
謝謝。
Operator
Operator
Chris Schott, JPMorgan.
克里斯‧肖特,摩根大通。
Ekaterina Knyazkova - Analyst
Ekaterina Knyazkova - Analyst
Hey, thank you so much. This is Ekaterina on for Chris. So first just on RYTARY, any line of sight of when we could see generic entry. Just wondering if you heard anything from the channel on when Teva could potentially launch. And can you just remind us of what you're embedding in guidance for the year? And then on CREXONT -- and then on '26 outlook, it's obviously early, but any initial thoughts on pushes and pulls investors should keep in mind for next year? Thank you.
嘿,非常感謝。這裡是葉卡捷琳娜,替克里斯報道。首先,就 RYTARY 而言,任何能夠讓我們看到通用入口的視線。想問你有沒有從通路聽到關於梯瓦製藥可能何時上市的消息?您能否提醒我們一下,今年的指導方針中包含了哪些內容?然後是關於 CREXONT——以及關於 2026 年的展望,現在顯然還為時過早,但對於投資者明年應該記住的推動因素和拉動因素,您有什麼初步的想法嗎?謝謝。
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Anastasios Konidaris - Chief Financial Officer, Executive Vice President
Hey, Ekaterina, I'll take the first RYTARY question and then if you don't mind repeating your second question on CREXONT. So a couple of things. So on RYTARY, we have no new indication of whatever may or may not happen there. Earlier on this month, we launched our own authorized generics with a partner.
嘿,Ekaterina,我先回答你關於 RYTARY 的第一個問題,如果你不介意的話,再重複你關於 CREXONT 的第二個問題。有兩件事。所以,關於RYTARY,我們沒有任何新的跡象表明那裡可能會發生什麼事,或者不會發生什麼事。本月初,我們與合作夥伴推出了我們自己的授權仿製藥。
So this was part of a well-documented settlement years ago, and we are receiving the majority of potential profits that may come up on that authorized generic.
這是多年前一項有據可查的和解協議的一部分,我們將獲得該授權仿製藥可能產生的絕大部分潛在利潤。
So overall, the delay of Teva has always been a positive for us. And it's going to be positive I believe for both this year and next year.
所以總的來說,Teva的延期對我們來說一直是件好事。我相信這對今年和明年都會是積極的。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Yeah. I think the second one, Ekaterina, is the 2026 as we mentioned in our script, momentum is already here. The approvals we listed it on page 11 of the company presentation, it tells you that the excitement over the new product launches. Current business is performing really well. So we expect continued growth in 2026 and beyond.
是的。我認為第二個,葉卡捷琳娜,是 2026 年,正如我們在劇本中提到的,勢頭已經到來。我們在公司簡報第 11 頁列出的審批情況表明,大家對新產品的發布感到非常興奮。目前業務發展勢頭良好。因此,我們預計2026年及以後將持續成長。
Ekaterina Knyazkova - Analyst
Ekaterina Knyazkova - Analyst
Thank you.
謝謝。
Operator
Operator
David Amsellem, Piper Sandler.
大衛·阿姆塞勒姆,派珀·桑德勒。
David Amsellem - Senior Research Analyst
David Amsellem - Senior Research Analyst
So just a couple for me. Wanted to pick your brain on the bXOLAIR biosimilar. It doesn't look like a particularly crowded market potentially. So how are you thinking about that opportunity? So that's number one.
我就幾個。想請教一下關於bXOLAIR生物相似藥的問題。看起來這似乎不是一個特別擁擠的市場。你對這個機會有什麼看法?這是第一點。
Number two, can you just give us a better sense of how many biosimilars you're looking to file annually and specifically how you're thinking about Part B versus say Part D products and where your priorities lie in terms of whether it's a retail pharmacy setting or institutional setting?
第二,您能否更清楚說明您每年計劃提交多少生物相似藥申請,特別是您如何看待 B 部分產品與 D 部分產品,以及您在零售藥房環境還是機構環境中的優先事項是什麼?
So just philosophically wanted to get your thoughts on that. And then lastly on the DHE autoinjector, how are you thinking about that opportunity, and what that market looks like, given that it's particularly crowded, acute migraine space? Thank you.
所以,我只是想從哲學角度聽聽你對此的看法。最後,關於 DHE 自動注射器,您如何看待這個市場機遇,以及考慮到急性偏頭痛市場競爭特別激烈,您認為這個市場前景如何?謝謝。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
David, bXOLAIR biosimilars, we're pleased that we have filed the product. Our partner has manufacturing capabilities right here in the United States, and it will have additional capacity outside of United States as well. So we obviously would maximize the assets.
David,關於 bXOLAIR 生物類似藥,我們很高興已經提交了該產品的申請。我們的合作夥伴在美國本土擁有生產能力,在美國以外地區也擁有額外的產能。所以,我們顯然會最大限度地利用資產。
We use our relationship that we have built over 20-plus years to the same groups of buyers and with 300 products. So we have a deep relationship with whether it's CVS, Caremark, Optum, United, Express Script, Cigna.
我們利用與同一批買家建立的 20 多年的關係,向他們推銷 300 多種產品。因此,我們與 CVS、Caremark、Optum、United、Express Scripts、Cigna 等公司都建立了深厚的合作關係。
We enjoy very deep relationship as well as Pfizer and Primes and other smaller private labels. So one market we would be exploring is the private label, which could be very significant in two-player market as the product by itself is growing 32% for the brand.
我們與輝瑞、Primes 以及其他一些規模較小的自有品牌保持著非常深厚的合作關係。因此,我們將探索的一個市場是自有品牌,這在雙雄市場中可能非常重要,因為產品本身就能為品牌帶來 32% 的成長。
So very excited about that. And then also there is when you are first to, you typically have the bigger coverage from the PBM, so your other potential customers tend to use your products as well. So we'll maximize the market opportunity for bXOLAIR for sure in advance of approval, which is expected in the fourth quarter next year.
對此我感到非常興奮。此外,如果你是第一個這樣做,你通常會從藥品福利管理機構 (PBM) 獲得更大的覆蓋範圍,因此你的其他潛在客戶也傾向於使用你的產品。因此,我們一定會在 bXOLAIR 獲得批准之前,盡量利用其市場機會,預計批准時間為明年第四季。
On your question on -- I'll continue on the market first, the Part B, Part D. So as you know, we've been vocal about the vertical integration is must, the licensing deals are pretty much dead. That business model will not work, and we I've said that five years ago, and it's not like I'm a very genius guy.
關於你提出的問題-我先繼續談市場,然後是B部分和D部分。如你所知,我們一直強調垂直整合是必須的,授權協議基本上已經過時了。這種商業模式行不通,我五年前就說過,而且我也不是什麼天才。
It's just like what happened in generics. As you know, the complex generics or generics, the room for two margins in the United States market it makes it harder; harder for to have a real play in biosimilars.
這就像仿製藥領域發生的情況一樣。如您所知,複雜的仿製藥或仿製藥,美國市場上只有兩倍的利潤空間,這使得生物相似藥的真正發展更加困難。
So whoever is vertically integrated is going to benefit big time, especially companies having current capabilities of working on five, seven biosimilars per year and filing those. Those will be the winner. And those are obviously filed globally. So I don't see any difference whether it's Part B, Part D. We're going to play in broader biosimilars.
因此,任何實現垂直整合的公司都將從中受益匪淺,尤其是那些目前有能力每年研發五到七個生物相似藥並提交申請的公司。他們將成為贏家。而這些文件顯然是全球存檔的。所以我覺得無論是B部分還是D部分,都沒有什麼差別。我們將涉足更廣泛的生物相似藥領域。
And obviously, once the vertical integration is done, we would obviously expand the capabilities into bispecific and ADC. If you're in biologics, then you can do more biologics. So that's where we will look forward to. And also FDA is considering a 505(b)(2) pathway for branded biologics. So that could be exciting as well to bring early access to some of these lifesaving drugs or critical drugs, critical medicines.
顯然,一旦垂直整合完成,我們肯定會將能力擴展到雙特異性抗體和ADC領域。如果你從事生物製劑行業,那麼你就可以做更多生物製劑。所以,這就是我們所期待的。此外,FDA 正在考慮為品牌生物製劑開闢 505(b)(2) 途徑。因此,能夠儘早獲得一些救命藥或關鍵藥物,也是一件令人興奮的事情。
So we're excited on that. We will play on Part B, Part D, private label, the smaller customers, the insurance coverage. We will be everywhere. I don't see any difference for us, Amneal or major competitors, to not be pretty much in all segments of the market. DHE, it is very exciting.
我們對此感到很興奮。我們將著眼於B部分、D部分、自有品牌、小客戶和保險覆蓋範圍。我們將無所不在。我認為,對於我們Amneal或主要競爭對手來說,沒有涉足幾乎所有細分市場並沒有什麼區別。DHE,這太令人興奮了。
You know the market, right. CGRP, the triptans. But there are almost -- our internal analysis we have put it out there. 132,000 patients fail those first- and second-line therapies. So they're being administered with the well-proven DHE autoinjection in the hospital.
你了解市場,對吧?CGRP,曲坦類藥物。但實際上,根據我們內部的分析,我們已經公佈了結果。大約有13.2萬名患者對第一線和二線療法無效。所以,他們在醫院接受了經過驗證的DHE自動注射治療。
We made it autoinjectors so they can administer at home avoiding going to emergency rooms, wait time, travel time. So it's a very useful innovation for patients. And so far, we're getting -- it's very early in the inning but getting great feedback. We've got the team all engaged with the key headache centers and key KOLs. So remains -- you'll see our progress.
我們將其製成自動注射器,以便他們可以在家中自行注射,避免去急診室、等待時間和路程時間。所以這對患者來說是一項非常有用的創新。到目前為止,我們得到的回饋非常好——雖然現在還處於比賽初期,但已經得到了很好的回饋。我們已經讓團隊與主要痛點中心和關鍵意見領袖進行了溝通。所以剩下的就是——你會看到我們的進展。
I don't have any prediction. We've been saying the $50 million to $100 million peak sales. So we'll update as we go.
我沒有任何預測。我們一直說銷售高峰將達到 5,000 萬美元至 1 億美元。我們會隨時更新進展。
Ekaterina Knyazkova - Analyst
Ekaterina Knyazkova - Analyst
Okay, thank you.
好的,謝謝。
Operator
Operator
Thank you. There are no questions waiting at this time. I will pass the conference back over to Chirag Patel for any additional remarks.
謝謝。目前沒有待解答的問題。我將把會議交還給奇拉格·帕特爾,讓他補充發言。
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director
Well thank you very much everyone. Have a great day. Thanks.
非常感謝大家。祝你有美好的一天。謝謝。
Anthony Dimeo - Head of Investor Relations
Anthony Dimeo - Head of Investor Relations
Thank you.
謝謝。